Navigation Links
Agendia Appoints New CEO and Supervisory Board Member
Date:10/24/2011

IRVINE, California and AMSTERDAM, October 24, 2011 /PRNewswire/ --

Agendia, an innovative molecular diagnostics company, today announced that its supervisory board of directors has appointed David Macdonald as chief executive officer. This follows the resignation of the company's co-founder and chief executive officer, Dr. Bernhard Sixt. Dr. Sixt will remain with the company in an advisory capacity. Agendia also announced the addition of Dr. Colin Goddard, executive chairman and acting CEO of privately held biotechnology firm Coferon, Inc., to its supervisory board of directors.

"On behalf of Agendia's board and all its employees, I would like to personally extend my deepest gratitude to Dr. Sixt for his leadership in making this company an internationally recognized innovator in the molecular diagnostic space," said Hessel Lindenbergh, chairman of Agendia's supervisory board. "David Macdonald is an accomplished leader in our industry and I have no doubt that under his leadership, Agendia will continue to thrive."

Macdonald has served as Agendia's COO since April 2010 and brings with him more than 25 years of international experience developing and commercializing clinical diagnostics and laboratory services for companies including Nova Biomedical, Behring Diagnostics, Nichols Institute and Quest Diagnostics. He has held CEO and COO roles for the past 18 years. He holds a Bachelor of Science degree from Northeastern University in management and finance as well as an MBA from Babson College.

Dr. Goddard served as CEO of OSI Pharmaceuticals, Inc. and as a member of the company's board of directors until it's $4 billion acquisition by Astellas Pharmaceuticals, Inc. in July of 2010. He currently serves as executive chairman and acting CEO of Coferon, Inc., a privately held biotechnology platform company. He is also a director of biotechnology companies PanOptica and Human Genome Sciences, Inc. Dr. Goddard is actively involved as an advisor to several venture capital firms and other industry groups.

"I'm pleased to welcome Collin Goddard to our supervisory board of directors. He brings with him a wealth of knowledge in the biotechnology sector and will be an asset to Agendia moving forward," said Lindenbergh.

About Agendia:

Agendia is an international molecular diagnostic company, focused on the discovery and development of tools to improve the quality of life for cancer patients, by providing healthcare professionals with critical information that enables personalized treatment.   Agendia's Symphony™ suite of breast cancer products is based on genomic analysis of an individual patient's tumor biology, providing unprecedented insight for complex treatment decisions. Symphony includes MammaPrint, the first and only FDA-cleared breast cancer recurrence assay, as well as BluePrint, a molecular subtyping assay, TargetPrint®, an ER/PR/HER2 expression assay, and TheraPrint®, a therapy selection assay. Together, these tests help physicians determine a patient's individual risk for metastasis, which patients will benefit from chemo or hormonal therapy, and which patients do not require these treatments and can instead be treated with other less arduous and costly methods. For additional information, please visit http://www.agendia.com.


'/>"/>
SOURCE Agendia B.V.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Agendia Launches TargetPrint(R) for Breast Cancer Patients
2. Agendias MammaPrint(R) Included in 2008 Dutch Institute for Healthcare Improvement CBO Guidelines
3. Agendia Supports High Profile CME Symposium and Presents Compelling Data at the 2008 San Antonio Breast Cancer Symposium
4. Agendias MammaPrint(R) Predicts Response to Neoadjuvant Chemotherapy in Breast Cancer
5. Agendias Breast Cancer Test MammaPrint(R) Identifies New Subset of Low Risk HER2+ Patients
6. Agendias Breast Cancer Recurrence Test MammaPrint Included in International St. Gallen Expert Consensus Recommendations
7. /C O R R E C T I O N -- Agendia B.V./
8. FDA Broadens Clearance for Agendias MammaPrint(R)
9. Agendia to Play Pivotal Role in ISPY-2 Trial for Breast Cancer
10. Agendia to Provide Testimony at Public Meeting on FDA Oversight of Laboratory-Developed Tests
11. Agendia Inaugurates New State-of-the-Art Genomics Laboratory in Irvine
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/20/2017)... , April 20, 2017 Research ... Pharmacogenomics Market Size, Market Share, Application Analysis, Regional Outlook, Growth ... report to their offering. ... The global pharmacogenomics market was valued at US$ 7,167.6 ... Mn by 2024, expanding at a CAGR of 5.6% from ...
(Date:4/20/2017)... -- Research and Markets has announced the addition ... Analysis By Service (Manufacturing, Research), By Country, (Brazil, Mexico, Colombia, ... report to their offering. ... The Latin American pharmaceutical contract manufacturing services market is ... Low drug registration cost in Latin American countries and continuous ...
(Date:4/19/2017)... , April 19, 2017 The Mobile X-Ray product ... a healthy CAGR during the forecast period Mobile ... the global digital mobile X-Ray devices market, which is estimated ... 2017, expanding at a CAGR of 7% over the forecast ... opportunity of more than US$ 100 Mn in 2017 over ...
Breaking Medicine Technology:
(Date:4/21/2017)... , ... April 21, 2017 , ... ... weeklong campaign, AWARE: A Week of Addiction and Recovery Education, from April 24 ... treating and preventing substance use disorders. , The mission of AWARE is ...
(Date:4/21/2017)... ... April 21, 2017 , ... Northern California Medical Associates ... Spring Symposium on April 1, 2017 in Santa Rosa. This well-attended annual conference ... providers an opportunity to learn about cutting edge treatments, to collaborate, share research ...
(Date:4/21/2017)... ... April 21, 2017 , ... Providing for loved ones before one’s passing is ... where to even begin. “Now more than ever there are some questions that are ... and your family,” said attorney Lisa Edgar Dickman, founder of the Law Offices of ...
(Date:4/21/2017)... , ... April 21, 2017 , ... Yisrayl Hawkins, Pastor and Overseer at The House ... leaders in hopes of squashing a global crisis with solution to peace plan. Yisrayl says ... work because the plan is given by the Creator Himself. , Yisrayl says war ...
(Date:4/21/2017)... Texas (PRWEB) , ... April 21, 2017 , ... ... sound familiar? These are five common elements between the Obamacare program that ... hog control program which uses Warfarin poison to kill hogs. , Like ...
Breaking Medicine News(10 mins):